# ELTK (ELTK) — Financial Analysis

**Exchange:** Unknown  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-17  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/eltk/thesis · /memo/eltk

## Financial Snapshot

### Step 04 — Financial Statement Quality and Adjustments

**Company:** Eltek Ltd (ELTK) | **Date:** 2026-06-17

---

#### 1. Key Findings

- **Reported earnings quality is high; the accounting is clean and conservative.** SBC is immaterial (~$0.5M/yr, ~1% of revenue) [S2], there are no aggressive non-GAAP adjustments (management's only adjusted metric is plain-vanilla EBITDA), revenue recognition is point-in-time on shipment, and cash flow has historically tracked or exceeded net income [S2]. The earnings problem at Eltek is *operational* (margin), not *quality* (accounting).
- **The FY2025 margin collapse is ~⅔ transitory and ~⅓ sticky.** Management's three causes — (a) production-relocation/start-up inefficiency [genuinely one-time], (b) ~$2.2M FX drag from USD weakness [exogenous, recurring risk], (c) wage inflation [sticky] [S1][S3]. For a normalized earnings base, (a) reverses, (b) is a wash over a cycle but unhedgeable, and (c) stays — so normalized gross margin should sit *below* the FY2023 28% peak but well above the FY2025 15% trough.
- **Do NOT anchor normalized earnings on reported FY2013 or FY2021 net income** — both were inflated by large one-time tax benefits ($2.98M deferred-tax release in FY2013; $3.54M tax benefit in FY2021) [S2]. FY2021's $0.86 EPS is *not* a clean operating year. The cleanest "good-times" operating references are **FY2023 (28.1% GM, 15.6% OM)** and **FY2024 (22.2% GM, 9.4% OM)** [S2].
- **The Nistec related-party web is disclosed and stated arm's-length, but is a structural governance discount, not a fraud flag.** Sales to Nistec ($1.66M, 3.2% of revenue, +116% over 2 yrs), a $417K/yr management fee paid to Nistec, and capped services purchased from Nistec [S1] — all related-party, all approved, none hidden. Quality concern is *alignment*, addressed in Steps 08/17.
- **Adversarial sweep: CLEAN.** No short-seller reports, fraud allegations, class actions, SEC investigations, or whistleblower complaints found targeting Eltek as of 2026-06-17; short interest is negligible (~0.3%, down 33% recently) [S4][S5]. The only documented items are minor Israeli **environmental penalties** and **historical Nasdaq listing-compliance scares (2017–2018)** during the last deep trough — both resolved [S1][S6].

**Net for thesis:** Net positive on quality — the numbers can be trusted, and the trough is operational/transitory in large part — which is precisely what makes the recovery case investable rather than a value trap built on suspect accounting.

#### 2. Implications for Thesis and Valuation

- **Normalized earnings base for valuation (Steps 13–14):** start from the operating P&L (not reported tax-distorted NI). A reasonable normalized gross margin lands in the **22–26%** band (above FY2025's 15%, at/below FY2023's 28%), reflecting reversal of relocation drag but persistence of higher wages. Tax should be normalized to the ~16–23% Israeli range (Preferred Enterprise 16% election available), not the distorted single-digit/benefit years [S1][S2].
- **EBITDA is a usable proxy** here (clean adjustments, low SBC), but capitalize the operating lease (~$1.2M/yr → PV into debt) and treat the capacity capex cycle explicitly — FCF has been negative two years on the build, so EV/EBITDA on trough EBITDA (107x) is meaningless; normalized EBITDA (~$5–6M at recovery) is the right denominator [S1][S2].
- **Clean adversarial record removes the tail-risk discount** a controlled micro-cap might otherwise carry — there is no Muddy-Waters-style overhang. The governance discount is purely the Nistec alignment/minority question, not integrity.

#### 3. Objective

Convert reported numbers into an analytically usable earnings base; test "one-time" items for recurrence; analyze SBC, FX, tax, leases, related-party, and accruals; and run the mandatory adversarial sweep.

#### 4. Narrative Analysis

**Reconciling reported to usable.** Eltek's statements are U.S. GAAP, audited (EY/Kost Forer since FY2024; Deloitte/Brightman through FY2023 — a routine auditor transition with both reports in the FY2025 20-F and no disclosed disagreement) [S1]. Management presents EBITDA as its headline adjusted metric, and the bridge is unremarkable: FY2025 net income $0.8M + D&A $2.1M + interest + tax ≈ EBITDA $4.5M [S2]. There is no parade of "adjusted" add-backs — no recurring "restructuring," no serial "one-time" items inflating a non-GAAP number. That alone distinguishes Eltek from many micro-caps.

**Are the "one-time" margin items really one-time?** This is the crux of Step 04. Management attributes the FY2025 gross-margin fall (22.2%→15.4%) to three things [S1][S3]: (1) **production-relocation and new-line start-up inefficiency** — genuinely transitory; once the lines are qualified and relocation is digested, under-absorption reverses; (2) **~$2.2M FX drag** from the ~12.5% USD depreciation vs. NIS — exogenous and unhedgeable, a wash over a full cycle but a recurring *risk*, not a one-time charge; (3) **wage inflation** for skilled operators — *sticky*; this does not reverse. The honest conclusion: roughly two-thirds of the compression (relocation + the cyclical part of FX) should reverse, but a portion (wages) is permanent — so normalized margin is below the 28% peak. The Q1 2026 gross loss adds a fourth, temporary factor: an unusually low-priced shipment mix (older backlog) [S3].

**SBC, tax, leases.** SBC is trivially small (~$0.5–0.6M/yr) and already expensed — no dilution game [S2]. Tax is the main reported-NI distortion historically: FY2013 and FY2021 carried large one-time benefits ($2.98M, $3.54M) that make those years' EPS unrepresentative [S2]; the plant's "Benefited/Preferred Enterprise" status offers a ~16% rate option, and $10.8M of capital-loss carryforwards exist but only shelter capital gains (limited operating value) [S1]. The single ~90,000 sq ft plant is an operating lease (~$1.2M/yr, extended to 2039), carried as an ROU asset/liability — for valuation it should be PV'd into a debt-like obligation [S1].

**Accruals / cash conversion.** No red flags. FY2023 CFO ($8.9M) exceeded NI ($6.4M); FY2025 CFO ($1.1M) modestly exceeded NI ($0.8M) despite a ~$3.7M working-capital build (inventory $11.2M and AR $14.8M grew as the company stocked materials and carried receivables through the transition) [S1][S2]. The inventory build is consistent with deliberate war-driven buffering management described, not channel-stuffing (there is no channel). The one capital-allocation oddity: a $1.276M dividend paid in FY2025 that *exceeded* net income and pushed retained earnings slightly negative [S2] — examined in Step 07.

**Adversarial sweep (mandatory) — results.** Multiple independent searches (short-seller reports; fraud/accounting allegations; class actions; SEC/regulatory investigations; named activist firms Hindenburg/Muddy Waters/Spruce Point/Kerrisdale/Viceroy; whistleblower/governance controversy) returned **no material adverse findings** [S4][S5]. Short interest is negligible (~5,700 shares, ~0.3% of shares, down 33% as of Mar 2026) — there is no active short thesis [S5]. Documented items, all disclosed and minor: (i) **Israeli environmental penalties** — ~$0.6M Clean Air (2019–20, paid, 10% refunded), ~$0.1M hazardous materials (2022, partially reduced), an ongoing soil/groundwater contamination investigation, and a Feb-2026 hearing summons over two 2025 hazardous-materials incidents [S1]; (ii) **historical Nasdaq listing-compliance scares** — minimum-bid-price (Jan 2017) and stockholders'-equity-below-$2.5M (Oct 2018) notices during the FY2016–18 loss trough, since cured [S6]. *(Namesake caution: "Eltek AS/Eltek Norway," a Delta-owned power-electronics firm, is unrelated.)* This is a positive finding worth stating plainly: **no integrity overhang.**

#### 5. Evidence and Sources

- Margin-compression attribution, related-party detail, tax/enterprise status, lease, environmental penalties: 20-F [S1].
- SBC, tax-benefit years, cash-flow/NI, working capital: XBRL [S2].
- FX magnitude, transition/wage commentary: transcripts [S3].
- Adversarial sweep: WebSearch results [S4][S5]; Nasdaq compliance history [S6].

#### 6. Assumption Register Updates

- **A15 (new):** Normalized gross margin ≈ 22–26% (relocation drag reverses; wage inflation sticky; below FY2023 28% peak) — **Judgment, High sensitivity** — feeds Steps 13–15 [S1][S2][S3].
- **A16 (new):** Exclude FY2013/FY2021 one-time tax benefits from any normalized-earnings anchor — Fact, Medium [S2].
- **A17 (new):** No integrity/short-seller overhang (adversarial sweep clean) — Fact, Low [S4][S5].

#### 7. Tables and Calculations

**Reported vs. quality-adjusted read [S1][S2]:**

| Item | Reported | Quality note |
|------|----------|--------------|
| SBC | ~$0.5M/yr (~1% rev) | Immaterial; no add-back games |
| Non-GAAP metric | EBITDA only | Clean bridge (NI + D&A + int + tax) |
| FY2013 NI $3.8M | incl. $2.98M tax benefit | One-time — exclude from normal |
| FY2021 NI $5.0M | incl. $3.54M tax benefit | One-time — exclude from normal |
| Operating lease | ~$1.2M/yr to 2039 | PV into debt for valuation |
| Related-party (Nistec) | $1.66M sales / $0.68M expense | Disclosed arm's-length; alignment flag |

**Margin-compression decomposition (FY2025) [S1][S3]:**

| Cause | ~Nature | Reverses? |
|-------|---------|-----------|
| Relocation / start-up inefficiency | One-time | Yes (on line completion) |
| FX (~$2.2M, USD −12.5% vs NIS) | Exogenous | Cyclical wash; unhedgeable |
| Wage inflation (skilled labor) | Structural | No (sticky) |

#### 8. Open Questions and Data Gaps

1. What gross margin does the plant actually print once relocation/ramp ends — closer to 22% or 26%? (Step 05, 13)
2. Will the environmental matters (Feb-2026 hazardous-materials hearing; soil/groundwater investigation) escalate beyond immaterial? (Step 11)
3. Q1 2026 debt: confirm the bank-line draw behind the new net-debt position (Step 06).

##### Next-Step Dependencies
Step 05 reads the normalized-margin band (A15) into the quarterly momentum and KPI build. Step 06 examines the Q1 2026 debt emergence. Steps 13–14 use the normalized-earnings base and the lease-capitalization note.

---

#### Source Index

| Tag | Document | Section | Date | Notes |
|-----|----------|---------|------|-------|
| [S1] | `ELTK_financials/sec_filings/20F_FY2025_summary.md` | Item 5; RP note; tax; environmental | 2026-06-17 | Margin causes, related-party, lease, penalties |
| [S2] | `ELTK_financials/xbrl/xbrl_summary.md` | IS/CF; tax-benefit footnotes | 2026-06-17 | SBC, one-time tax years, CFO vs NI |
| [S3] | `ELTK_financials/earnings/transcript_Q4_2025.md`, `transcript_Q1_2026.md` | Prepared + Q&A | 2026-06-17 | FX magnitude, transition/wage |
| [S4] | WebSearch — short/fraud/class-action/SEC + named activist firms | — | 2026-06-17 | No adverse findings |
| [S5] | MarketBeat / Nasdaq short interest | — | 2026-06-17 | ~0.3% short, down 33% |
| [S6] | WebSearch — SEC 6-K FY2017/2018 | Nasdaq compliance notices | 2026-06-17 | 2017 min-bid; 2018 equity <$2.5M (cured) |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ELTK/fundamental

## Navigation

- Overview: /stocks/eltk
- Financials (this page): /stocks/eltk/financials
- Thesis: /stocks/eltk/thesis
- Investment Memo: /memo/eltk
- Coverage universe: /stocks